Analyst Price Targets — XOMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 30, 2026 10:06 am | Joseph Pantginis | H.C. Wainwright | $39.00 | $40.99 | TheFly | Xoma downgraded to Neutral from Buy at H.C. Wainwright |
| February 24, 2026 11:08 am | — | Leerink Partners | $50.00 | $25.32 | TheFly | Xoma price target raised to $50 from $45 at Leerink |
| December 12, 2025 1:44 pm | — | Stifel Nicolaus | $50.00 | $25.78 | StreetInsider | Benchmark Reiterates Buy Rating on XOMA, Ltd. (XOMA) Despite Rezolute Setback |
| December 11, 2025 3:51 pm | Joseph Pantginis | H.C. Wainwright | $97.00 | $27.00 | TheFly | Xoma price target lowered to $97 from $104 at H.C. Wainwright |
| December 11, 2025 2:57 pm | David Risinger | Leerink Partners | $45.00 | $26.51 | TheFly | Xoma price target lowered to $45 from $58 at Leerink |
| December 9, 2025 11:45 am | — | UBS | $76.00 | $30.49 | TheFly | Xoma initiated with a Buy at Lucid Capital |
Latest News for XOMA
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq:…
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's (i) 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) (the “Series A Preferred Stock”) (984,000 shares outstanding, CUSIP No.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XOMA.
U.S. House Trading
No House trades found for XOMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.